Spruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants Life Science Investing
AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call Life Science Investing
GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness Life Science Investing
Biomind Labs Applauds Landmark Executive Order Accelerating Psychedelic Research and Access in The United States Life Science Investing
When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech Life Science Investing
PharmAla Biotech Positioned to Supply U.S. Expanded Access Pathway for MDMA Established by Presidential Executive Order Life Science Investing
PharmaTher's Microneedle Patch Platforms Positioned to Benefit from Major U.S. Catalysts in Psychedelics and Peptides Life Science Investing
Palvella Therapeutics to Present QTORIN Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026 Life Science Investing
Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region Life Science Investing
BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting Biotech Investing
Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 Life Science Investing
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board for Phase 3 Study in Metastatic Breast Cancer
